{
    "clinical_study": {
        "@rank": "28450", 
        "arm_group": {
            "arm_group_label": "Aloglipin 25mg, tablets, orally, once daily, up to 36 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of long-term treatment\n      with alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded\n      inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy,\n      exercise therapy, and \u03b1-glucosidase inhibitor.\n\n      In addition, examining the safety and efficacy of alogliptin in patients with renal\n      impairment, information on the appropriate dosage of alogliptin according to the severity of\n      impaired renal function should be collected."
        }, 
        "brief_title": "Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With \u03b1-GI\"", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "A special drug use surveillance is planned to examine the safety and efficacy of long-term\n      use of alogliptin in patients with type 2 diabetes mellitus under the daily clinical use\n      conditions.\n\n      Participants of this surveillance will be patients with type 2 diabetes mellitus who failed\n      to respond adequately to diet therapy and exercise therapy alone or to a combination of diet\n      therapy, exercise therapy, and \u03b1-glucosidase inhibitor. The planned sample size is 3,000\n      subjects.\n\n      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes mellitus who have not adequately responded to any one\n             of the following therapies:\n\n               1. Diet therapy and exercise therapy alone\n\n               2. In addition to diet therapy and exercise therapy, use of \u03b1-glucosidase inhibitor\n\n        Exclusion Criteria:\n\n          -  Patients contraindicated for Nesina\n\n               1. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes\n                  mellitus (these patients require prompt adjustment of hyperglycemia by fluid\n                  infusion and insulin, and hence use of Nesina is not appropriate.)\n\n               2. Patients with severe infection, pre- or post-operative patients, or patients\n                  with serious traumatic injury (blood glucose control by insulin injection is\n                  desirable for these patients, and hence use of Nesina is not appropriate.)\n\n               3. Patients with a history of hypersensitivity to any ingredient of Nesina"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with type 2 diabetes mellitus who have been examined at a medical institution"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945216", 
            "org_study_id": "121-011", 
            "secondary_id": "JapicCTI-132250"
        }, 
        "intervention": {
            "arm_group_label": "Aloglipin 25mg, tablets, orally, once daily, up to 36 months", 
            "description": "Alogliptin tablets", 
            "intervention_name": "Alogliptin", 
            "intervention_type": "Drug", 
            "other_name": "Nesina; SYR-322"
        }, 
        "intervention_browse": {
            "mesh_term": "Alogliptin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Nesina Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With \u03b1-GI\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
                "measure": "Frequency of Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 36 relative to baseline.", 
                "measure": "Change from Baselin in Glycosylated Hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 36"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in the value of fasting blood glucose collected at month 36 relative to baseline.", 
            "measure": "Change from Baselin in Fasting Blood Glucose", 
            "safety_issue": "No", 
            "time_frame": "Baseline and month 36"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}